Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Potassium Iodide Stockpiling Guidelines Called For In Bioterrorism Bill

This article was originally published in The Tan Sheet

Executive Summary

Within a year of enacting bioterrorism legislation, the Bush Administration will consult with federal, state and local agencies to establish guidelines for the stockpiling of potassium iodide (KI) tablets
Advertisement

Related Content

Bioterrorism Efforts At Forefront Of CFSAN Activities; GMPs Remain Priority
Bioterrorism Efforts At Forefront Of CFSAN Activities; GMPs Remain Priority
Bioterrorism Efforts At Forefront Of CFSAN Activities; GMPs Remain Priority
Potassium Iodide Tablets Preferable To Bulk Powders – ConsumerLab.com
Bioterrorism bill
FDA animal data efficacy rule
PDUFA III Authorizes FDA To Alert Doctors Of Failed Phase IV Commitments
PDUFA III Authorizes FDA To Alert Doctors Of Failed Phase IV Commitments
Potassium iodide
Potassium Iodide Education Efforts To Highlight Dosage, Timing Of Use

Topics

Advertisement
UsernamePublicRestriction

Register

PS094065

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel